Myriad Genetics, Inc. ( MYGN ) NASDAQ Global Select

Cena: 5.33 ( 4.1% )

Aktualizacja 06-26 22:00
NASDAQ Global Select
Branża: Medical - Diagnostics & Research
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 2 700
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 96%
Ilość akcji: 82 198 200
Debiut giełdowy: 1995-10-06
WWW: https://myriad.com
CEO: Mr. Paul J. Diaz J.D.
Adres: 320 Wakara Way
Siedziba: 84108 Salt Lake City
ISIN: US62855J1043
Opis firmy:

Myriad Genetics, Inc., firma zajmująca się badaniami genetycznymi i precyzyjnymi, rozwija i komercjalizuje testy genetyczne w Stanach Zjednoczonych i na arenie międzynarodowej. Firma oferuje molekularne testy diagnostyczne do stosowania w onkologii oraz zastosowaniach kobiet i zdrowia psychicznego. Zapewnia dziedziczny test raka Myrisk, test sekwencjonowania DNA do oceny ryzyka dla dziedzicznych nowotworów; Bracanaliza CDX Linia linii zarodkowej Taju diagnostyczne, test sekwencjonowania DNA, aby pomóc w określeniu terapii u pacjentów z przerzutową piersią, jajnikiem, przerzutowym rakiem trzustki lub przerzutowym rakiem prostaty z szkodliwymi lub podejrzanymi szkodliwymi wariantami BRCA; oraz MyChoice CDX Towarzysz diagnostyczny, test nowotworowy, który określa status niedoboru homologicznego rekombinacji u pacjentów z rakiem jajnika. Firma oferuje również test prognostyczny raka prostaty Prolaris, analizę guza ekspresji RNA w celu oceny agresywności raka prostaty; Endopredict Test prognostyczny raka piersi, test ekspresji RNA do oceny agresywności raka piersi; Precyzyjny guz, rozwiązanie dla precyzyjnej onkologii; i prequel prenatalny ekran, nieinwazyjny test badania przesiewowego przeprowadzonego przy użyciu krwi matki do badania ciężkich zaburzeń chromosomalnych u płodu. Ponadto przewiduje ekran przewoźnika Foresight, test prenatalny dla przyszłych rodziców w celu oceny ryzyka przekazania recesywnego stanu genetycznego na ich potomstwo; oraz Genesight Psychotropic Mental Health Test, test genotypowania DNA w celu ułatwiania selekcji leku psychotropowego u pacjentów cierpiących na depresję, lęk, ADHD i inne choroby psychiczne. Myriad Genetics, Inc. prowadzi strategiczną współpracę z Illumina, Inc. i Intermountain Precision Genomics w celu oferowania usług zarodkowych i somatycznych badań nowotworowych. Firma została założona w 1991 roku i ma siedzibę w Salt Lake City w stanie Utah.

Wskaźniki finansowe
Kapitalizacja (USD) 491 305 542
Aktywa: 1 081 300 000
Cena: 5.33
Wskaźnik Altman Z-Score: 2.0
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -4.8
Ilość akcji w obrocie: 96%
Średni wolumen: 2 260 888
Ilość akcji 92 177 400
Wskaźniki finansowe
Przychody TTM 823 600 000
Zobowiązania: 349 600 000
Przedział 52 tyg.: 3.81 - 29.3
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -1.1
P/E branży: 30.3
Beta: 1.937
Raport okresowy: 2025-08-04
WWW: https://myriad.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Mark S. Verratti Chief Commercial Officer 915 807 1968
Dr. Dale Muzzey Ph.D. Chief Scientific Officer 816 505 1980
Dr. Kevin Richard Haas Ph.D. Chief Technology Officer 580 360 1986
Mr. Samraat S. Raha Chief Operating Officer 514 758 1973
Mr. Paul J. Diaz Chief Executive Officer, President & Director 2 311 908 1962
Mr. Glenn Farrell Senior Vice President & Chief Marketing Officer 0 0
Mr. Justin Hunter Interim General Counsel & Corporate Secretary 0 0
Mr. Matthew Scalo Senior Vice President of Investor Relations 0 0
Mr. Scott J. Leffler Chief Financial Officer 0 1975
Ms. Natalie Munk Principal Accounting Officer 0 1981
Wiadomości dla Myriad Genetics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky About Fraud Investigation NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. accessnewswire.com 2025-05-16 14:12:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accessnewswire.com 2025-05-16 14:00:00 Czytaj oryginał (ang.)
Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. accessnewswire.com 2025-05-15 14:30:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accessnewswire.com 2025-05-15 14:00:00 Czytaj oryginał (ang.)
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46 th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. globenewswire.com 2025-05-14 20:45:00 Czytaj oryginał (ang.)
MYGN ALERT: Ongoing Investigation Into Myriad Genetics, Inc. - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. accessnewswire.com 2025-05-14 14:15:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accessnewswire.com 2025-05-14 14:00:00 Czytaj oryginał (ang.)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Myriad Genetics, Inc. (MYGN) NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. accessnewswire.com 2025-05-13 18:45:00 Czytaj oryginał (ang.)
Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. accessnewswire.com 2025-05-13 18:30:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accessnewswire.com 2025-05-13 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accessnewswire.com 2025-05-12 23:15:00 Czytaj oryginał (ang.)
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On M. businesswire.com 2025-05-08 21:28:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights b. businesswire.com 2025-05-08 19:51:00 Czytaj oryginał (ang.)
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com 2025-05-08 14:35:44 Czytaj oryginał (ang.)
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2025, Myriad released its first quarter 2025 financi. businesswire.com 2025-05-08 02:59:00 Czytaj oryginał (ang.)
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025. zacks.com 2025-05-07 13:35:40 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Tycho Peterson - Jefferies Lu Li - UBS Operator Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Matt Scalo, Senior Vice President of Investor Relations. seekingalpha.com 2025-05-07 03:35:09 Czytaj oryginał (ang.)
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-05-07 00:35:32 Czytaj oryginał (ang.)
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago. zacks.com 2025-05-06 22:40:49 Czytaj oryginał (ang.)
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million  declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year. globenewswire.com 2025-05-06 20:05:00 Czytaj oryginał (ang.)
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025. benzinga.com 2025-02-25 16:22:06 Czytaj oryginał (ang.)
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024. zacks.com 2025-02-25 11:55:32 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript Myriad Genetics, Inc. (NASDAQ:MYGN ) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Scott Leffler - Chief Financial Officer Conference Call Participants Madeline Mollman - Wolfe Research Will Ortmayer - Goldman Sachs Madison Pasterchick - Morgan Stanley Tycho Peterson - Jefferies Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Hallum Puneet Souda - Leerink Partners Ben Mee - Stephens Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. seekingalpha.com 2025-02-24 22:03:05 Czytaj oryginał (ang.)
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-24 22:00:27 Czytaj oryginał (ang.)
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago. zacks.com 2025-02-24 21:00:34 Czytaj oryginał (ang.)
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-over-year, benefiting from improving revenue per test trends and greater laboratory efficiencies. globenewswire.com 2025-02-24 18:05:00 Czytaj oryginał (ang.)
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. globenewswire.com 2025-02-24 10:30:00 Czytaj oryginał (ang.)
Myriad Genetics Included in Forbes America's Best Employers 2025 List SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America's Best Employers 2025. globenewswire.com 2025-02-19 10:30:00 Czytaj oryginał (ang.)
MYGN Stock Might Rise on Collaboration With CancerCARE Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test. zacks.com 2025-02-11 12:31:51 Czytaj oryginał (ang.)
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE's network to assess their eligibility for the MyRisk test by taking the MyGeneHistory ® quiz, a guideline-based online patient screening tool. globenewswire.com 2025-02-06 10:30:00 Czytaj oryginał (ang.)
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad's ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market. US patent No. globenewswire.com 2025-02-05 18:15:00 Czytaj oryginał (ang.)
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad's advanced molecular diagnostic tests — Prolaris ® Prostate Cancer Test and MyRisk ® Hereditary Cancer Test – into Lumea's digital pathology platform, BxLink™. globenewswire.com 2025-02-05 10:30:00 Czytaj oryginał (ang.)
Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). globenewswire.com 2025-01-29 10:30:00 Czytaj oryginał (ang.)
MYGN Stock Gains Following the Launch of Know More Sooner Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing. zacks.com 2025-01-24 10:36:14 Czytaj oryginał (ang.)
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. The “Know More Sooner” website provides the benefits and dispels the common myths of prenatal genetic testing, as well as where to get screened and what actions can be taken in the instance of a high-risk result. globenewswire.com 2025-01-23 10:30:00 Czytaj oryginał (ang.)
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal). globenewswire.com 2025-01-21 10:30:00 Czytaj oryginał (ang.)
MYGN Stock Gains Following Collaboration With Hannah Storm Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador. zacks.com 2025-01-10 10:21:22 Czytaj oryginał (ang.)
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. globenewswire.com 2025-01-09 18:30:00 Czytaj oryginał (ang.)
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. globenewswire.com 2025-01-08 13:27:00 Czytaj oryginał (ang.)
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). globenewswire.com 2025-01-08 10:00:00 Czytaj oryginał (ang.)
MYGN Stock Might Gain From the New Recognition of RiskScore Study The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine. zacks.com 2024-12-20 10:55:18 Czytaj oryginał (ang.)
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine. globenewswire.com 2024-12-19 18:15:00 Czytaj oryginał (ang.)
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? Strategic progress and solid potential in oncology testing keep MYGN on investors' radar. zacks.com 2024-12-17 09:26:28 Czytaj oryginał (ang.)
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. Since the announcement, Myriad has actively engaged in constructive dialogue with UNH regarding the clinical evidence supporting Myriad's proprietary and clinically differentiated mental health medication test, GeneSight, including presenting additional clinical data to UnitedHealthcare for its further review and consideration. globenewswire.com 2024-12-10 20:26:00 Czytaj oryginał (ang.)
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members. globenewswire.com 2024-12-10 18:05:00 Czytaj oryginał (ang.)
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment. zacks.com 2024-12-10 10:01:11 Czytaj oryginał (ang.)
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. globenewswire.com 2024-12-09 18:05:00 Czytaj oryginał (ang.)
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay. zacks.com 2024-11-25 09:41:29 Czytaj oryginał (ang.)
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina's updated comprehensive gene panel assay, TruSight™ Oncology 500 v2. globenewswire.com 2024-11-20 18:30:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Myriad Genetics, Inc. (MYGN) NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. accesswire.com 2024-11-18 12:30:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / November 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accesswire.com 2024-11-18 12:00:00 Czytaj oryginał (ang.)
MYGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Myriad Genetics, Inc. Shareholders Who Lost Money NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. accesswire.com 2024-11-17 19:07:00 Czytaj oryginał (ang.)
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. globenewswire.com 2024-11-17 18:00:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MYGN NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. accesswire.com 2024-11-17 12:45:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accesswire.com 2024-11-17 12:00:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. (MYGN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. accesswire.com 2024-11-15 12:15:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accesswire.com 2024-11-15 12:00:00 Czytaj oryginał (ang.)
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm NEW YORK--(BUSINESS WIRE)---- $MYGN #MYGN--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cov. businesswire.com 2024-11-14 18:00:00 Czytaj oryginał (ang.)
Myriad Genetics, Inc. Being Investigated on Behalf of Myriad Genetics, Inc. Investors. Contact Levi & Korsinsky For Details NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. accesswire.com 2024-11-14 12:30:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN. accesswire.com 2024-11-14 12:00:00 Czytaj oryginał (ang.)